Investment Update February 2025



W A M Active

ASX: WAA

Mispricing opportunities in the Australian market.







Net Tangible Assets (NTA) per share before tax

February 2025

82.78c

January 2025

85.61c

The net current and deferred tax asset/(liability) position of the Company for February 2025 is 8.44 cents per share. This includes 9.83 cents per share of income tax losses available to the Company in future periods.

Dividend highlights

6.0c

Annualised fully franked interim dividend (per share)

98.7c

Dividends paid since inception (per share)

141.0c

Dividends paid since inception, when including the value of franking credits (per share)

6.8%

Annualised fully franked interim dividend yield*

9.7%

Grossed-up dividend yield*

17.7c

Profits reserve (per share)

Assets

\$64.1m

Investment portfolio performance (pa since inception January 2008)

11.2%

Bloomberg AusBond Bank Bill Index: 2.9%

Month-end share price

(at 28 February 2025)


\$0.88


*Based on the 28 February 2025 share price and the annualised FY25 fully franked interim dividend of 6.0 cents per share. Grossed-up dividend yield includes the value of franking credits and is based on a tax rate of 30%.

Investment portfolio performance is before expenses, fees and taxes to compare to the relevant index which is also before expenses, fees and taxes.



Read Sam Koch's comments > on Chemist Warehouse success





The WAM Active (ASX: WAA) investment portfolio decreased in February. A key contributor was out-of-home media company oOh!media (ASX: OML) while medical imaging services provider Integral Diagnostics (ASX: IDX) detracted from investment portfolio performance.




oOh!media is a leading out-of-home media company that connects businesses with diverse public audiences. During the month, oOh!media announced its CY2024 full year results, posting a total revenue of \$636 million and adjusted underlying earnings before interest, taxes, depreciation and amortisation (EBITDA) of \$129 million, in line with the December 2024 trading update. We were pleased to see that the momentum in performance has accelerated in CY2025 to date, and oOh!media's commitment to delivering best-in-class services and assets to its clients will drive future market share.



Integral Diagnostics provides diagnostic services to patients. In February, the company announced its FY2025 interim results, which fell short of market expectations, leading to a drop in its share price. It posted a statutory loss after tax of \$0.4 million, driven by a continued clinical staff shortage and higher-than-expected labour cost inflation, especially in regional Australia. Despite these challenges, we were pleased to see solid revenue growth and believe that the previously completed merger with Capitol Health will provide Integral Diagnostics with increased scale, improving margins and driving growth in metropolitan areas.

Fully franked dividends since inception


The Board declared a fully franked interim dividend of 3.0 cents per share payable on 30 April 2025.



Our proven investment process

Market Driven Process

Takes advantage of short-term mispricing opportunities in the Australian equity market.




A major event that alters the market's perception of a company or its earnings potential which leads to a rerating of the investee company's share price.

Top 20 holdings (in alphabetical order)

| Code | Company Name |
|--------|------------------------------|
| 360 | Life360 Inc. |
| A2M | The a2 Milk Company |
| ALQ | ALS |
| ASB | Austal |
| CAR | CAR Group |
| GDG | Generation Development Group |
| HSN | Hansen Technologies |
| HUB | HUB24 |
| IDX | Integral Diagnostics |
| KBC | Keybridge Capital |
| OML | oOh!media |
| ORI | Orica |
| PBH | PointsBet Holdings |
| PYC | PYC Therapeutics |
| QOR | Qoria |
| SEK | SEEK |
| SRG | SRG Global |
| SUM NZ | Summerset Group |
| TLX | Telix Pharmaceuticals |
| WEB | WEB Travel Group |

Diversified investment portfolio by sector



- Consumer discretionary: 18.0%
- Financials: 15.9%
- Information technology: 12.5%
- Industrials: 14.1%
- Health care: 13.4%
- Communication Services: 7.4%
- Materials: 6.5%
- Consumer staples: 5.5%
- Real estate: 5.3%
- Cash: 1.4%

About the Investment Manager



Wilson Asset Management has a track record of making a difference for shareholders and the community for 27 years.

As the investment manager for eight leading listed investment companies (LICs) and two unlisted funds, Wilson Asset Management has a diversified offering of Australian and global listed equities and alternative assets.

Wilson Asset Management created and is the lead supporter of the first LICs to deliver both investment and social returns: Future Generation Australia (ASX: FGX) and Future Generation Global (ASX: FGG), as well as Future Generation Women.

| >\$5.9 billion | in funds under management |
|----------------|--------------------------------|
| 130,000 | retail and wholesale investors |
| >250 years | combined investment experience |
| 11 | investment products |

Listed Investment Companies

W A M Capital

W | A | M Leaders

W A M Global

W A Microcap

W A M Alternative Assets

W | **A** | **M** Strategic Value

W A M Research

W A M Active

Key contacts

Geoff Wilson AO Chairman & Chief Investment Officer X (Twitter) @GeoffWilsonWAM

(02) 9247 6755

Kate Thorley **Chief Executive Officer** (02) 9247 6755

Jesse Hamilton Chief Financial Officer 0401 944 807

Camilla Jones Corporate Affairs Manager 0407 407 062

For more information visit: wilsonassetmanagement.com.au









Stav informed

Please subscribe to our newsletter and follow us on our social channels X, LinkedIn and Facebook for real-time insights and market updates from our investment experts. along with the latest news, results and events.

Zenith Disclaimer: The Zenith Investment Partners (ABN 27 103 132 672, AFS Licence 226872) ("Zenith") rating (ASX:WAA assigned June 2024) referred to in this piece is limited to "General Advice" (\$766B Corporations Act 2001) for Wholesale clients only. This advice has been prepared without taking into account the objectives, financial situation or needs of any individual, including target markets of financial products, where applicable, and is subject to change at any time without prior notice. It is not a specific recommendation to purchase, sell or hold the relevant product(s). Investors should seek independent financial advice before making an investment decision and should consider the appropriateness of this advice in light of their own objectives, financial situation and needs. Investors should obtain a copy of and consider the PDS or offer document before making any decision and refer to the full Zenith Product Assessment available on the Zenith website. Past performance is not an indication of future performance. Zenith usually charges the product issuer, fund manager or related party to conduct Product Assessments. Full details regarding Zenith's methodology, ratings definitions and regulatory compliance are available on our Product Assessments and at Fund Research Regulatory Guidelines.

Independent Investment Research (IIR) Disclaimer: The rating ascribed by IIR is provided under the Annual LIC Research Participation Scheme whereby the LIC Manager provides information and IIR rating is monitored on a monthly basis to ensure its currency. The manager is a participant and as such this rating is current. Please note an ascribed rating does not constitute advice in any form. We recommend to any reader that no investment decisions are made on this fund without seeking advice from your Wealth Manager